BIOSPAIN 2026

Europe has no shortage of ambitious strategies for biotechnology. The challenge now is implementation.
Delivering a competitive, resilient and sustainable European agri-food biotechnology ecosystem will require coordinated action across industry, startups, academia, investors, farmers, policymakers and innovation organisations. No single stakeholder can deliver this transformation alone.
This roundtable will build on the key insights and recommendations collected by the EU Agri-Food Biotech Alliance from representatives from across the entire value chain—including the European Commission, EFSA, industry leaders, startups, investors, research organisations, farmers, retailers and ecosystem partners—to identify the priorities and actions needed to accelerate biotechnology adoption in Europe.
The discussion will focus on how organisations can work together to reduce fragmentation, align around common priorities, launch collaborative initiatives and create greater impact through collective action. The session will conclude with a call for organisations across the value chain to join the effort and help shape a stronger, more connected European agri-food biotechnology ecosystem.

1. Conselleiro de Educación, Ciencia, Universidades y FP (Nota: Este seria nuestro Conselleiro, es donde esta integrada la Agencia Gallega de Innovación(GAIN))
Román Rodríguez González
Mails:
[email protected] (Conselleiro de Educación, Ciencia, Universidades y FP)
[email protected] (Jefe Gabinete Conselleiro)
[email protected] (Secretaria Conselleiro)
2. Conselleiro de Sanidad
Antonio Gómez Caamaño
Mails:
[email protected] (Conselleiro de Sanidad)
[email protected] (Jefa Gabinete Conselleiro)
[email protected] (Secretaria Conselleiro)

Regional biotechnology clusters and associations play a vital role in strengthening the biotechnology ecosystem by promoting collaboration among stakeholders, facilitating knowledge transfer, and accelerating the scientific and business development of the sector. Their work enhances the competitiveness of biotechnology companies while reinforcing the innovation and growth potential of their respective regions.

The aim of this session is to examine the role of biotechnology clusters in the development of the sector, explore how they collaborate with one another, and identify the key strengths and challenges across different regions, highlighting both shared priorities and the distinctive characteristics of each regional ecosystem. The discussion will also address the Biotech Act proposal to promote networks of biotechnology clusters as a means of strengthening competitiveness and fostering collaboration across the European biotechnology sector.

Propuesta de Ponentes: 

Moderador: Acesabio o bien AseBio y metemos a Acesabio como ponente?

• Idoia Muñoz, Directora del BHC
• Robert Fabregat, Director general de Biocat
• Jesús Agüero, Director Bioval
• Zara Pons, General Manager BIOIB
• Loli Pereiro, Manager Bioga

Imagine a crossroads where human health, animal welfare, and the environment meet — and a new generation of sentinels stands guard. This panel will convene those sentinels to tackle the urgent challenge of protecting vulnerable people and animals from disease driven by major antibiotic‑resistant threats, and to showcase the bleeding‑edge tools that spot and dissect multidrug‑resistant bacteria across clinical, food and environmental landscapes within a One Health framework. We’ll voyage through the knotted realities of vaccine development and market access, then move into the fast‑moving world of diagnostics: gene‑based LAMP assays that turn hours into minutes, electrochemical biosensors that read microbial whispers as electrical signals, nanomaterial‑amplified methods that reveal the faintest traces of pathogens, microfluidic “lab on a chip” platforms that miniaturize whole laboratories, and point‑of‑care systems built for real‑world decisions. The growing appreciation for vaccines—from immune surrogates of protection to fresh insights into host‑pathogen dynamics and sharper disease definitions—will be explored as a keystone for prevention. Recent breakthroughs already sound like science fiction: sub‑hour detection of key AMR genes, ultra‑low limits of detection in messy samples, and real‑time antimicrobial susceptibility testing that brings clinical and research timelines into alignment. These advances not only sharpen bedside decision making but also feed drug discovery with high‑resolution pathogen profiles that accelerate new antimicrobial development. The panel will bring together thought leaders in vaccines, diagnostics, microfluidics, biosensing, environmental microbiology, and pharmaceutical innovation to chart the next frontiers in AMR detection — and to imagine how those frontiers will reshape the hunt for tomorrow’s drugs.


Introduction – The One Health Challenge of MDR Bacteria (5 min)
Block 1 - From Immunity to Impact: Building Executable AMR Vaccines (15 min)
Block 2 – Genetic Detection of MDR Bacteria: LAMP and Other Rapid Molecular Techniques (15 min)
Block 3 – Electrochemical Biosensing: Fast, Sensitive Characterization of MDR Bacteria (15 min)
Block 4 – Point of Care Devices and Lab on a Chip Systems for Rapid AMR Decision-Making (15 min)
Block 5 – Connecting Diagnostics to Drug Development: The Feedback Loop (10 min)